Tonix Pharmaceuticals Holding (STU:TPM0) Growth Rank : 0 (As of Jun. 08, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Tonix Pharmaceuticals Holding Growth Rank?

Tonix Pharmaceuticals Holding has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Tonix Pharmaceuticals Holding Growth Rank Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding (STU:TPM0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (STU:TPM0) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

TNXP:USA

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Tonix Pharmaceuticals Holding (STU:TPM0) Headlines

No Headlines